Evidence map›Paper›PMID 38361000›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection.

Mark A Frye, Charles B Nemeroff

Open access · hybridAbstract readLetter
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mark A FryeDepartment of Psychiatry & Psychology, Mayo Clinic, Mayo Clinic Alix School of Medicine, Rochester, MN, USA. MFrye@mayo.edu.ORCID http://orcid.org/0000-0001-6997-4215
Charles B NemeroffDepartment of Psychiatry & Behavioral Sciences, University of Texas at Austin Dell Medical School, Austin, TX, USA.ORCID http://orcid.org/0000-0001-7867-1160
Mayo Clinic in Arizona · USThe University of Texas at Austin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PharmacogeneticsPharmacogenomic TestingAntidepressive AgentsAntidepressive Agents

Identifiers

PMID38361000
PMCPMC10948788
OpenAlexW4391844929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.